<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004114</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067340</org_study_id>
    <secondary_id>UCLA-9902026</secondary_id>
    <secondary_id>NCI-G99-1603</secondary_id>
    <nct_id>NCT00004114</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer</brief_title>
  <official_title>Non-Myeloablative Chemotherapy Followed by Unrelated Allogeneic Stem Cell Transplantation in Patients With Advanced Hematologic Malignancies: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Peripheral stem cell transplantation may be able to replace&#xD;
      immune cells that were destroyed by chemotherapy used to kill cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of chemotherapy plus peripheral stem cell&#xD;
      transplantation in treating patients who have advanced hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the feasibility of allogeneic engraftment after unrelated matched&#xD;
      allogeneic peripheral blood stem cell transplantation preceded by a nonmyeloablative,&#xD;
      fludarabine based conditioning regimen in patients with advanced hematologic malignancies.&#xD;
      II. Determine the toxicities of this regimen, especially graft versus host disease, in these&#xD;
      patients.&#xD;
&#xD;
      OUTLINE: Patients receive fludarabine IV over 30-60 minutes on days -7 to -4,&#xD;
      cyclophosphamide IV over 30 minutes on days -7 to -5, and cytarabine IV over 2 hours on days&#xD;
      -4 and -3. Allogeneic peripheral blood stem cells are infused on day 0. Filgrastim (G-CSF) is&#xD;
      administered IV over 1 hour or subcutaneously beginning on day 1 and continuing until blood&#xD;
      counts recover. Patients are followed weekly until day 60 and then monthly for 10 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never opened&#xD;
  </why_stopped>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven advanced hematologic malignancy unsuitable&#xD;
        for standard allogeneic bone marrow transplantation One of the following types: Refractory&#xD;
        or relapsed acute myelogenous or lymphocytic leukemia Over 55 years Chronic myelogenous&#xD;
        leukemia and failed interferon treatment Over 55 years Lymphoma, chronic lymphocytic&#xD;
        leukemia, Hodgkin's disease, or multiple myeloma: Refractory OR More than 2 relapses OR&#xD;
        Relapse after autologous peripheral blood stem cell transplantation Myelodysplastic&#xD;
        syndrome other than refractory anemia Severe aplastic anemia Under 55 years and either&#xD;
        organ dysfunction or not eligible for standard allogeneic bone marrow transplant due to one&#xD;
        or more of the following: Chronic hepatitis LVEF less than 50% Karnofsky less than 70%&#xD;
        Unrelated matched donor available&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: See Disease Characteristics Adult Performance status: See&#xD;
        Disease Characteristics Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: Not&#xD;
        specified Hepatic: See Disease Characteristics SGOT/SGPT no greater than 4 times upper&#xD;
        limit of normal Renal: Creatinine no greater than 2 mg/dL Cardiovascular: See Disease&#xD;
        Characteristics Pulmonary: DLCO at least 50% predicted Other: Not pregnant or nursing&#xD;
        Negative pregnancy test Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: Not&#xD;
        specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not&#xD;
        specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos E. Emmanouilides, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>February 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2004</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

